Absolute balder dash. Go and speak to a Professor in medicine. Reputational risk is second only to malpractice lawsuit fear.
My discussion on the trial and this KOL presso' drew your rude scathing. You know expect me to entertain you in wider criticism of lack of peer reveiw Zecs (which NO-ONE disputed)? NO the discussion was specifically per the thread, these phase II results going to KOL's.
"But how does that compare to standard care? What percentage were cured? After how long? How severe was baseline? What else were the participants taking? Why didn't they include an active control?"
It was a phase II safety and efficacy trial. Active control groups are not always used in smaller phase II trials and again you show you did not actually listen the the webinar, or understand the subject on which you speak. They explained their exclusion of a control group on ethical grounds. BUt again, single arm trials not entirely unusual in phase II trials - if not my personal preference.
The things you are asking for will tend to be answered in phase III trials, particularly via secondary endpoints. Perhaps you missed it in the ASX release, this one is about to start ("Phase III start H1 2025") and will, accordingly for phase III trials have a nice control group for you (I would imagine the placebo is more likely a SOC control group - no one, particularly I, ever said these lot were great in their execution), and actually have a large enough sample size to explore many of and hopefully other, secondary data points you seek with statistical confidence.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)